Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-03874-6, published online 21 August 2025.
In the version of this article initially published, the panel shown as Fig. 4b was a duplicate of Fig. 4a and has now been replaced. In the “GD2–CART01 manufacturing and characteristics of the DPs” section, in the text now reading “The single manufacturing failure occurred due to not achieving the required percentage of CD3+ cells, resulting in a final product containing 60.7% CD3+ cells and 37.5% natural killer (NK) cells,” 60.7%, the count also including NKT cells, replaces the original “11.6%.” The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Locatelli, F., Pagliara, D., De Ioris, M.A. et al. Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03996-x
Published:
DOI: https://doi.org/10.1038/s41591-025-03996-x
